Tweet

Session 303
Benefits to Academia and Industry of Diverse Strategic Alliances Based on Platform Technologies

Cancer Research UK has established two strategic alliances with AstraZeneca both involving platform technologies. CRUK AstraZeneca Antibody Alliance Laboratory focuses on developing diagnostic and therapeutic antibodies using AstraZeneca's world class antibody drug discovery capability, and Functional Genomics Centre using state of the art CRISPR technology to support target identification and validation.

The presentation and discussion will focus on benefits of both alliances particularly the value proposition supporting the academic ecosystem to help translate novel science, and ability to take on higher risk projects that pharma would not traditionally consider.

Panelists will share how the models came about and how they operate in standalone laboratories with strong matrix management involving CRUK employees and lab heads seconded from AstraZeneca.

Take-aways will include:

Speakers:

Julie Little, CA-AM, RTTP
Strategic Alliance Executive
Cancer Research UK

 

 

Kristina Tubby, PhD, CA-AM
Strategic Alliance Manager
Cancer Research UK

Kristina is a Strategic Alliance Manager at Cancer Research UK. She joined CRUK in 2015 after completing her PhD in Developmental Biology at UCL. On joining CRUK, Kris worked in the Strategic Partnerships team identifying, developing and establishing research partnerships with other non-profit organisations. In 2019, Kris joined CRUK's Commercial Partnerships team as a Strategic Alliance Manager and supports the delivery of CRUK's alliances with industry partners. Kris has played a key role in establishing the Joint AZ-CRUK Functional Genomics Centre and continues to be responsible for the management of CRUK business activities within the FGC.

David Andrews, PhD, FRSC
Pre-clinical Director, External R&D and Strategic Alliances
AstraZeneca